Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Role of DNA Repair and Protective Components in Bacillus subtilis Spore Resistance to Inactivation by 400 nm Blue Light.

Djouiai B, Thwaite JE, Laws TR, Commichau FM, Setlow B, Setlow P, Moeller R.

Appl Environ Microbiol. 2018 Jul 27. pii: AEM.01604-18. doi: 10.1128/AEM.01604-18. [Epub ahead of print]

PMID:
30054368
2.

A Novel Stochastic Multi-Scale Model of Francisella tularensis Infection to Predict Risk of Infection in a Laboratory.

Carruthers J, López-García M, Gillard JJ, Laws TR, Lythe G, Molina-París C.

Front Microbiol. 2018 Jul 6;9:1165. doi: 10.3389/fmicb.2018.01165. eCollection 2018.

3.

Bioscavenger is effective as a delayed therapeutic intervention following percutaneous VX poisoning in the guinea-pig.

Mann TM, Price ME, Whitmore CL, Perrott RL, Laws TR, McColm RR, Emery ER, Tattersall JEH, Green AC, Rice H.

Toxicol Lett. 2018 Sep 1;293:198-206. doi: 10.1016/j.toxlet.2017.11.029. Epub 2017 Nov 26.

PMID:
29183815
4.

Deep Sequencing of RNA from Blood and Oral Swab Samples Reveals the Presence of Nucleic Acid from a Number of Pathogens in Patients with Acute Ebola Virus Disease and Is Consistent with Bacterial Translocation across the Gut.

Carroll MW, Haldenby S, Rickett NY, Pályi B, Garcia-Dorival I, Liu X, Barker G, Bore JA, Koundouno FR, Williamson ED, Laws TR, Kerber R, Sissoko D, Magyar N, Di Caro A, Biava M, Fletcher TE, Sprecher A, Ng LFP, Rénia L, Magassouba N, Günther S, Wölfel R, Stoecker K, Matthews DA, Hiscox JA.

mSphere. 2017 Aug 23;2(4). pii: e00325-17. doi: 10.1128/mSphereDirect.00325-17. eCollection 2017 Jul-Aug.

5.

Demonstrating the Protective Efficacy of the Novel Fluoroquinolone Finafloxacin against an Inhalational Exposure to Burkholderia pseudomallei.

Barnes KB, Hamblin KA, Richards MI, Laws TR, Vente A, Atkins HS, Harding SV.

Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e00082-17. doi: 10.1128/AAC.00082-17. Print 2017 Jul.

6.

A comparison of host gene expression signatures associated with infection in vitro by the Makona and Ecran (Mayinga) variants of Ebola virus.

Bosworth A, Dowall SD, Garcia-Dorival I, Rickett NY, Bruce CB, Matthews DA, Fang Y, Aljabr W, Kenny J, Nelson C, Laws TR, Williamson ED, Stewart JP, Carroll MW, Hewson R, Hiscox JA.

Sci Rep. 2017 Feb 27;7:43144. doi: 10.1038/srep43144.

7.

Transcriptomic signatures differentiate survival from fatal outcomes in humans infected with Ebola virus.

Liu X, Speranza E, Muñoz-Fontela C, Haldenby S, Rickett NY, Garcia-Dorival I, Fang Y, Hall Y, Zekeng EG, Lüdtke A, Xia D, Kerber R, Krumkamp R, Duraffour S, Sissoko D, Kenny J, Rockliffe N, Williamson ED, Laws TR, N'Faly M, Matthews DA, Günther S, Cossins AR, Sprecher A, Connor JH, Carroll MW, Hiscox JA.

Genome Biol. 2017 Jan 19;18(1):4. doi: 10.1186/s13059-016-1137-3.

8.

Antibacterial Activity of Blue Light against Nosocomial Wound Pathogens Growing Planktonically and as Mature Biofilms.

Halstead FD, Thwaite JE, Burt R, Laws TR, Raguse M, Moeller R, Webber MA, Oppenheim BA.

Appl Environ Microbiol. 2016 Jun 13;82(13):4006-4016. doi: 10.1128/AEM.00756-16. Print 2016 Jul 1.

9.

A Comparison of the Adaptive Immune Response between Recovered Anthrax Patients and Individuals Receiving Three Different Anthrax Vaccines.

Laws TR, Kuchuloria T, Chitadze N, Little SF, Webster WM, Debes AK, Saginadze S, Tsertsvadze N, Chubinidze M, Rivard RG, Tsanava S, Dyson EH, Simpson AJ, Hepburn MJ, Trapaidze N.

PLoS One. 2016 Mar 23;11(3):e0148713. doi: 10.1371/journal.pone.0148713. eCollection 2016.

10.

Immune profiling of the progression of a BALB/c mouse aerosol infection by Burkholderia pseudomallei and the therapeutic implications of targeting HMGB1.

Laws TR, Clark GC, D'Elia RV.

Int J Infect Dis. 2015 Nov;40:1-8. doi: 10.1016/j.ijid.2015.09.003. Epub 2015 Sep 7.

11.

"FoxP3 Hunting" during infection with Francisella tularensis.

D'Elia RV, Laws TR, Núñez A, Clark GC.

Int J Immunopathol Pharmacol. 2014 Oct-Dec;27(4):585-95. doi: 10.1177/039463201402700414.

PMID:
25572738
12.

Modeling early events in Francisella tularensis pathogenesis.

Gillard JJ, Laws TR, Lythe G, Molina-París C.

Front Cell Infect Microbiol. 2014 Dec 11;4:169. doi: 10.3389/fcimb.2014.00169. eCollection 2014.

13.

Delayed presence of alternatively activated macrophages during a Francisella tularensis infection.

D'Elia RV, Laws TR, Núñez A, Taylor C, Clark GC.

Microb Pathog. 2015 Jan;78:37-42. doi: 10.1016/j.micpath.2014.10.002. Epub 2014 Oct 2.

PMID:
25284816
14.

Protection against experimental melioidosis following immunisation with a lipopolysaccharide-protein conjugate.

Scott AE, Ngugi SA, Laws TR, Corser D, Lonsdale CL, D'Elia RV, Titball RW, Williamson ED, Atkins TP, Prior JL.

J Immunol Res. 2014;2014:392170. doi: 10.1155/2014/392170. Epub 2014 May 7.

15.

Vaccination with recombinant adenoviruses expressing Ebola virus glycoprotein elicits protection in the interferon alpha/beta receptor knock-out mouse.

O'Brien LM, Stokes MG, Lonsdale SG, Maslowski DR, Smither SJ, Lever MS, Laws TR, Perkins SD.

Virology. 2014 Mar;452-453:324-33. doi: 10.1016/j.virol.2013.03.028. Epub 2014 Jan 24.

16.

CpG oligonucleotides protect against Venezuelan equine encephalitis virus infection in a route-dependent manner.

Rees DG, Phillpotts RJ, Griffin KF, Lukaszewski RA, Laws TR, Atkins HS, Krieg AM, Titball RW.

Int J Antimicrob Agents. 2013 Dec;42(6):587-8. doi: 10.1016/j.ijantimicag.2013.09.001. Epub 2013 Oct 1. No abstract available.

PMID:
24210643
17.

In vivo manipulation of γ9(+) T cells in the common marmoset (Callithrix Jacchus) with phosphoantigen and effect on the progression of respiratory melioidosis.

Laws TR, Nelson M, Bonnafous C, Sicard H, Taylor C, Salguero FJ, Atkins TP, Oyston PC, Rowland CA.

PLoS One. 2013 Sep 30;8(9):e74789. doi: 10.1371/journal.pone.0074789. eCollection 2013.

18.

Targeting the "Rising DAMP" during a Francisella tularensis Infection.

D'Elia RV, Laws TR, Carter A, Lukaszewski R, Clark GC.

Antimicrob Agents Chemother. 2013 Sep;57(9):4222-4228. doi: 10.1128/AAC.01885-12. Epub 2013 Jun 24.

19.

Differential role for interleukin-6 during Francisella tularensis infection with virulent and vaccine strains.

Laws TR, Clark G, D'Elia RV.

Infect Immun. 2013 Aug;81(8):3055-6. doi: 10.1128/IAI.00234-13. Epub 2013 May 28. No abstract available.

20.

Exploitation of bacterial N-linked glycosylation to develop a novel recombinant glycoconjugate vaccine against Francisella tularensis.

Cuccui J, Thomas RM, Moule MG, D'Elia RV, Laws TR, Mills DC, Williamson D, Atkins TP, Prior JL, Wren BW.

Open Biol. 2013 May 22;3(5):130002. doi: 10.1098/rsob.130002.

21.

Protection against experimental melioidosis following immunization with live Burkholderia thailandensis expressing a manno-heptose capsule.

Scott AE, Laws TR, D'Elia RV, Stokes MG, Nandi T, Williamson ED, Tan P, Prior JL, Atkins TP.

Clin Vaccine Immunol. 2013 Jul;20(7):1041-7. doi: 10.1128/CVI.00113-13. Epub 2013 May 15.

22.

Trimethoprim/sulfamethoxazole (co-trimoxazole) prophylaxis is effective against acute murine inhalational melioidosis and glanders.

Barnes KB, Steward J, Thwaite JE, Lever MS, Davies CH, Armstrong SJ, Laws TR, Roughley N, Harding SV, Atkins TP, Simpson AJ, Atkins HS.

Int J Antimicrob Agents. 2013 Jun;41(6):552-7. doi: 10.1016/j.ijantimicag.2013.02.007. Epub 2013 Mar 19.

PMID:
23517714
23.

Assessment of antimicrobial peptide LL-37 as a post-exposure therapy to protect against respiratory tularemia in mice.

Flick-Smith HC, Fox MA, Hamblin KA, Richards MI, Jenner DC, Laws TR, Phelps AL, Taylor C, Harding SV, Ulaeto DO, Atkins HS.

Peptides. 2013 May;43:96-101. doi: 10.1016/j.peptides.2013.02.024. Epub 2013 Mar 14.

PMID:
23500517
24.

Experimental respiratory Marburg virus haemorrhagic fever infection in the common marmoset (Callithrix jacchus).

Smither SJ, Nelson M, Eastaugh L, Laws TR, Taylor C, Smith SA, Salguero FJ, Lever MS.

Int J Exp Pathol. 2013 Apr;94(2):156-68. doi: 10.1111/iep.12018. Epub 2013 Feb 27.

25.

An assessment of common marmoset (Callithrix jacchus) γ9(+) T cells and their response to phosphoantigen in vitro.

Rowland CA, Laws TR, Oyston PC.

Cell Immunol. 2012 Dec;280(2):132-7. doi: 10.1016/j.cellimm.2012.12.002. Epub 2012 Dec 19.

PMID:
23399838
26.

Evidence of arbovirus co-infection in suspected febrile malaria and typhoid patients in Nigeria.

Baba M, Logue CH, Oderinde B, Abdulmaleek H, Williams J, Lewis J, Laws TR, Hewson R, Marcello A, D' Agaro P.

J Infect Dev Ctries. 2013 Jan 15;7(1):51-9. doi: 10.3855/jidc.2411.

27.

Comparison of total antibody and interferon-γ T-cell responses in patients following infection with brucellosis in Georgia.

Akhvlediani T, Chitadze N, Laws TR, Makharadze M, Chubinidze M, Tsanava Sh, Commander NJ, Perkins SD, Dyson EH, Rivard RG, Hepburn MJ, Simpson AJ, Imnadze P, Trapaidze N.

J Infect Public Health. 2012 Oct;5(5):321-31. doi: 10.1016/j.jiph.2012.03.006. Epub 2012 Sep 24.

28.

Peripheral human γδ T cells control growth of both avirulent and highly virulent strains of Francisella tularensis in vitro.

Rowland CA, Hartley MG, Flick-Smith H, Laws TR, Eyles JE, Oyston PC.

Microbes Infect. 2012 Jul;14(7-8):584-9. doi: 10.1016/j.micinf.2012.02.001. Epub 2012 Feb 11.

PMID:
22370220
29.

Neutrophils are the predominant cell-type to associate with Burkholderia pseudomallei in a BALB/c mouse model of respiratory melioidosis.

Laws TR, Smither SJ, Lukaszewski RA, Atkins HS.

Microb Pathog. 2011 Dec;51(6):471-5. doi: 10.1016/j.micpath.2011.07.002. Epub 2011 Jul 20.

PMID:
21798336
30.

Inhibition of Francisella tularensis LVS infection of macrophages results in a reduced inflammatory response: evaluation of a therapeutic strategy for intracellular bacteria.

D'Elia R, Jenner DC, Laws TR, Stokes MG, Jackson MC, Essex-Lopresti AE, Atkins HS.

FEMS Immunol Med Microbiol. 2011 Aug;62(3):348-61. doi: 10.1111/j.1574-695X.2011.00817.x. Epub 2011 Jun 16.

31.

Yersinia pseudotuberculosis is resistant to killing by human neutrophils.

Laws TR, Davey MS, Green C, Cooper IA, Titball RW, Lukaszewski RA.

Microbes Infect. 2011 Jun;13(6):607-11. doi: 10.1016/j.micinf.2011.02.004. Epub 2011 Feb 24.

PMID:
21354325
32.

Evaluation of azithromycin, trovafloxacin and grepafloxacin as prophylaxis for experimental murine melioidosis.

Kenny DJ, Sefton AM, Brooks TJ, Laws TR, Simpson AJ, Atkins HS.

Int J Antimicrob Agents. 2010 Jul;36(1):87-9. doi: 10.1016/j.ijantimicag.2010.03.019. Epub 2010 May 11.

PMID:
20462743
33.

Neutrophils are important in early control of lung infection by Yersinia pestis.

Laws TR, Davey MS, Titball RW, Lukaszewski R.

Microbes Infect. 2010 Apr;12(4):331-5. doi: 10.1016/j.micinf.2010.01.007. Epub 2010 Jan 28.

PMID:
20114086
34.

Efficacy of moxifloxacin or gatifloxacin as prophylaxis against experimental murine Brucella melitensis infection.

Atkins HS, Spencer S, Brew SD, Laws TR, Thirlwall RE, MacMillan AP, Brooks TJ, Simpson AJ.

Int J Antimicrob Agents. 2009 Nov;34(5):471-3. doi: 10.1016/j.ijantimicag.2009.06.018. Epub 2009 Aug 13.

PMID:
19682862
35.

The cationic peptide magainin II is antimicrobial for Burkholderia cepacia-complex strains.

Thwaite JE, Humphrey S, Fox MA, Savage VL, Laws TR, Ulaeto DO, Titball RW, Atkins HS.

J Med Microbiol. 2009 Jul;58(Pt 7):923-9. doi: 10.1099/jmm.0.008128-0. Epub 2009 Jun 5.

PMID:
19502364
36.

Differential cell surface properties of vegetative Bacillus.

Thwaite JE, Laws TR, Atkins TP, Atkins HS.

Lett Appl Microbiol. 2009 Mar;48(3):373-8. doi: 10.1111/j.1472-765X.2008.02543.x. Epub 2009 Feb 2.

37.

CpG used as an adjuvant for an adenovirus-based Venezuelan equine encephalitis virus vaccine increases the immune response to the vector, but not to the transgene product.

Perkins SD, Williams AJ, O'Brien LM, Laws TR, Phillpotts RJ.

Viral Immunol. 2008 Dec;21(4):451-7. doi: 10.1089/vim.2008.0052.

PMID:
19115934
38.

Protection afforded against aerosol challenge by systemic immunisation with inactivated Francisella tularensis live vaccine strain (LVS).

Eyles JE, Hartley MG, Laws TR, Oyston PC, Griffin KF, Titball RW.

Microb Pathog. 2008 Feb;44(2):164-8. Epub 2007 Aug 21.

PMID:
17904793
39.

The pathogen Pseudomonas aeruginosa negatively affects the attraction response of the nematode Caenorhabditis elegans to bacteria.

Laws TR, Atkins HS, Atkins TP, Titball RW.

Microb Pathog. 2006 Jun;40(6):293-7. Epub 2006 May 6.

PMID:
16678995
40.

The nematode Panagrellus redivivus is susceptible to killing by human pathogens at 37 degrees C.

Laws TR, Smith SA, Smith MP, Harding SV, Atkins TP, Titball RW.

FEMS Microbiol Lett. 2005 Sep 1;250(1):77-83.

41.

Age influences resistance of Caenorhabditis elegans to killing by pathogenic bacteria.

Laws TR, Harding SV, Smith MP, Atkins TP, Titball RW.

FEMS Microbiol Lett. 2004 May 15;234(2):281-7.

42.

A liquid-based method for the assessment of bacterial pathogenicity using the nematode Caenorhabditis elegans.

Smith MP, Laws TR, Atkins TP, Oyston PC, de Pomerai DI, Titball RW.

FEMS Microbiol Lett. 2002 May 7;210(2):181-5.

Supplemental Content

Support Center